E

Elicera Therapeutics AB
STO:ELIC

Watchlist Manager
Elicera Therapeutics AB
STO:ELIC
Watchlist
Price: 5.59 SEK 3.52% Market Closed
Market Cap: 271.3m SEK

Operating Margin
Elicera Therapeutics AB

-100.2%
Current
-257%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-100.2%
=
Operating Profit
-13.7m
/
Revenue
13.7m

Operating Margin Across Competitors

No Stocks Found

Elicera Therapeutics AB
Glance View

Market Cap
268.5m SEK
Industry
Biotechnology

Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.

ELIC Intrinsic Value
7.83 SEK
Undervaluation 29%
Intrinsic Value
Price
E
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-100.2%
=
Operating Profit
-13.7m
/
Revenue
13.7m
What is the Operating Margin of Elicera Therapeutics AB?

Based on Elicera Therapeutics AB's most recent financial statements, the company has Operating Margin of -100.2%.

Back to Top